May 20, 2021
Aurina to Present Supportive Aurora 2 Continuation Study Interim Analysis Demonstrating Long-term Safety & Efficacy of Lupkynis™ (Volclosporin) in Subjects with Lupus Nephritis
April 15, 2021
Aurinia Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
April 8, 2021
Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings
No current content.